Pittsburgh Surgical Outcomes Research Center
Transforming the conduct of clinical research

Sepsis restructures immune cells

Each year, at least 1.7 million Americans develop sepsis (previously ‘severe sepsis’), of which 270,000 will die. Globally sepsis afflicts 19 million people and incurs 5 million deaths. In the US, it is present in 6% of adult hospitalizations and causes 1 in 3 in-hospital deaths. With a case fatality rate of 15.6%, it is the 10th leading cause of death. But even after clinical resolution of their infection, and long after we discharge them from the hospital, these patients are not ‘cured.’ The long-term mortality is upwards of 9 times higher after treatment for community acquired pneumonia and higher than mortality after an initial hospitalization for heart failure, stroke or major fracture. Two- and 5-year mortality among individuals who had sustained sepsis were 28.8% and 43.8% compared with death rates of 2.6% and 8.3% among those who never developed sepsis. And this elevated risk is not explained by a higher burden of chronic diseases prior to the occurrence of infection. No, these people are on a different biological trajectory characterized by an elevated risk of death. We now show that sepsis induces a durable restructuring of the complex machinery regulating mitochondrial and cellular Ca2+ homeostasis that fundamentally alters the future phenotype and fate of the cell. These changes persist long after clinical resolution of sepsis and lead to profound alterations in Ca2+ signaling, oxidative metabolism, and the sensitivity to Ca2+-dependent cell death pathways. These post-sepsis changes underlie the elevated risk of long-term death observed in survivors. Yet, they can be modulated to offer a personalized approach to realign these biological trajectories to a more adaptive, healthy phenotype.

Research Faculty

Research Type